Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
44.42 USD | -1.54% | +9.15% | +62.02% |
04-19 | Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says | MT |
03-28 | Truist Securities Initiates Coverage on Merus With Buy Rating, $69 Price Target | MT |
Business Summary
Number of employees: 201
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Innovative Therapeutics
100.0
%
| 42 | 100.0 % | 44 | 100.0 % | +5.68% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Netherlands
100.0
%
| 42 | 100.0 % | 44 | 100.0 % | +5.68% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Bill Lundberg
CEO | Chief Executive Officer | 60 | 11/06/19 |
Gregory Perry
DFI | Director of Finance/CFO | 63 | 30/04/16 |
Chief Tech/Sci/R&D Officer | - | 30/11/16 | |
Chief Tech/Sci/R&D Officer | 56 | 30/04/21 | |
Andrew Joe
CTO | Chief Tech/Sci/R&D Officer | 58 | 26/07/20 |
Peter Silverman
COO | Chief Operating Officer | 46 | 31/01/17 |
John de Kruif
CTO | Chief Tech/Sci/R&D Officer | 60 | 31/03/07 |
Sherri L. Spear
IRC | Investor Relations Contact | - | - |
Ashley Pereira
LAW | General Counsel | - | 31/08/21 |
Shannon Campbell
PRN | Corporate Officer/Principal | - | 31/01/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Gregory Perry
DFI | Director of Finance/CFO | 63 | 30/04/16 |
Maxine Gowen
BRD | Director/Board Member | 66 | 27/05/21 |
Paolo Pucci
BRD | Director/Board Member | 63 | 29/06/20 |
Anand Mehra
CHM | Chairman | 48 | 25/08/15 |
Mark Iwicki
BRD | Director/Board Member | 57 | 30/04/15 |
Bill Lundberg
CEO | Chief Executive Officer | 60 | 11/06/19 |
Victor Sandor
BRD | Director/Board Member | 57 | 11/06/19 |
Len Kanavy
BRD | Director/Board Member | 62 | 30/06/18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 58,687,551 | 54,301,344 ( 92.53 %) | 0 | 92.53 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+64.04% | 2.65B | |
-2.63% | 102B | |
+1.62% | 96.29B | |
+1.51% | 22.18B | |
-16.67% | 21.2B | |
-8.68% | 18.31B | |
-38.74% | 17.38B | |
-13.21% | 16.36B | |
+5.41% | 13.97B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- MRUS Stock
- Company Merus N.V.